Clinical trial
Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions…
NCT00492284 · QLT Inc., Industry · Completed
Key facts
| NCT number | NCT00492284 |
|---|---|
| Title | Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) |
| Official title | A Multicenter, Randomized, Single-masked Study Comparing Reduced-fluence Visudyne®-Lucentis® Combination Therapies and Lucentis® Monotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to AMD. |
| Acronym | RADICAL |
| Lead sponsor | QLT Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Choroidal Neovascularization, Macular Degeneration |
| Intervention type | Drug |
| Interventions | verteporfin, ranibizumab, dexamethasone |
| Enrollment | 162 |
| Start date | Jul 1, 2007 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2010 |
| First posted | Jun 27, 2007 |
| Last update posted | Jun 2, 2011 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: